TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Cancer
Interventions: DRUG: TTX-080|DRUG: TTX-080|DRUG: pembrolizumab|DRUG: cetuximab
Sponsor: Tizona Therapeutics, Inc